New developments in osteoimmunology

Nature Reviews Rheumatology

Volumn 8, Issue 11, 2012, Pages 684-689

  Takayanagi, Hiroshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; DENOSUMAB; EPHRIN; EPHRIN B2; EPHRIN B4; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; LEPTIN RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SCLEROSTIN; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW EDEMA; BONE REMODELING; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG TARGETING; HELPER CELL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATION; LYMPHOCYTE FUNCTION; MOLECULAR INTERACTION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOIMMUNOLOGY; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STEM CELL NICHE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH17 CELL;

ALLERGY AND IMMUNOLOGY; ANIMALS; ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE REMODELING; HUMANS; OSTEOBLASTS; RANK LIGAND; RECEPTOR CROSS-TALK; T-LYMPHOCYTES;

EID: 84868488604     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.167     Document Type: Review

References (44)

1. Takayanagi, H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7, 292-304 (2007).
2. Seeman, E. & Delmas, P. D. Bone quality - the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354, 2250-2261 (2006).
3. Lorenzo, J., Horowitz, M. & Choi, Y. Osteoimmunology: interactions of the bone and immune system. Endocr. Rev. 29, 403-440 (2008).
4. Nakashima, T. & Takayanagi, H. Osteoimmunology: crosstalk between the immune and bone systems. J. Clin. Immunol. 29, 555-567 (2009).
5. Nagasawa, T. Microenvironmental niches in the bone marrow required for B-cell development. Nat. Rev. Immunol. 6, 107-116 (2006).
6. Kiel, M. J. & Morrison, S. J. Uncertainty in the niches that maintain haematopoietic stem cells. Nat. Rev. Immunol. 8, 290-301 (2008).
7. Takayanagi, H. Osteoimmunology and the effects of the immune system on bone. Nat. Rev. Rheumatol. 5, 667-676 (2009).
8. Takayanagi, H. et al. T cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408, 600-605 (2000).
9. Chiang, E. Y. et al. Targeted depletion of lymphotoxin-α-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat. Med. 15, 766-773 (2009).
10. Cohen, S. B. et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlledphase II clinical trial. Arthritis Rheum. 58, 1299-1309 (2008).
11. Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231-1234 (2011).
12. Onal, M. et al. RANKL expression by B lymphocytes contributes to ovariectomy-induced bone loss. J. Biol. Chem. 287, 29851-29860 (2012).
13. Xiong, J. et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 17, 1235-1241 (2011).
14. Green, E. A., Choi, Y. & Flavell, R. A. Pancreatic lymph node-derived CD4+CD25+ Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 16, 183-191 (2002).
15. Totsuka, T. et al. RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis. J. Immunol. 182, 6079-6087 (2009).
16. Loser, K. et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat. Med. 12, 1372-1379 (2006).
17. Tan, W. et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470, 548-553 (2011).
18. Rossi, S. W. et al. RANK signals from CD4+3- inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J. Exp. Med. 204, 1267-1272 (2007).
19. Akiyama, T. et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 29, 423-437 (2008).
20. Hikosaka, Y. et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 29, 438-450 (2008).
21. Lacey, D. L. et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401-419 (2012).
22. Mercier, F. E., Ragu, C. & Scadden, D. T. The bone marrow at the crossroads of blood and immunity. Nat. Rev. Immunol. 12, 49-60 (2011).
23. Calvi, L. M. et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841-846 (2003).
24. Zhang, J. et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836-841 (2003).
25. Arai, F. et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118, 149-161 (2004).
26. Kiel, M. J., Radice, G. L. & Morrison, S. J. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. Cell Stem Cell 1, 204-217 (2007).
27. Lymperi, S. et al. Strontium can increase some osteoblasts without increasing hematopoietic stem cells. Blood 111, 1173-1181 (2008).
28. Ding, L., Saunders, T. L., Enikolopov, G. & Morrison, S. J. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 481, 457-62 (2012).
29. Omatsu, Y. et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity 33, 387-399 (2010).
30. Yamazaki, S. et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 147, 1146-1158 (2012).
31. Mendez-Ferrer, S. et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466, 829-834 (2010).
32. Kollet, O. et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med. 12, 657-664 (2006).
33. Miyamoto, K. et al. Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J. Exp. Med. 208, 2175-2181 (2011).
34. Geffroy-Luseau, A., Jego, G., Bataille, R., Campion, L. & Pellat-Deceunynck, C. Osteoclasts support the survival of human plasma cells in vitro. Int. Immunol. 20, 775-782 (2008).
35. Li, H. et al. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood 116, 210-217 (2010).
36. Borrero, C. G., Mountz, J. M. & Mountz, J. D. Emerging MRI methods in rheumatoid arthritis. Nat. Rev. Rheumatol. 7, 85-95 (2011).
37. Li, P. et al. Systemic tumor necrosis factor α mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor α-transgenic mice. Arthritis Rheum. 50, 265-276 (2004).
38. Proulx, S. T. et al. Elucidating bone marrow edema and myelopoiesis in murine arthritis using contrast-enhanced magnetic resonance imaging. Arthritis Rheum. 58, 2019-2029 (2008).
39. Cain, C. J. et al. Absence of sclerostin adversely affects B cell survival. J. Bone Miner. Res. 27, 1451-1461 (2012).
40. Xian, L. et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat. Med. 18, 1095-1101 (2012).
41. Tang, Y. et al. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757-765 (2009)
42. Matsuo, K. & Irie, N. Osteoclast-osteoblast communication. Arch. Biochem. Biophys. 473, 201-209 (2008).
43. Negishi-Koga, T. et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat. Med. 17, 1473-1480 (2011).
44. Hayashi, M. et al. Osteoprotection by semaphorin 3A. Nature 485, 69-74 (2012).